September 15, 2021
The Alliance submitted a letter to the Senate Finance Committee supporting legislation to amend the 2021 Consolidated Appropriations Act (CAA) through reconciliation to ASP+15% for skin substitute products before new requirements under Part B go into effect next year. "This small change would allow skin substitute products to remain in private physician offices while retaining the new reporting requirements instituted in the omnibus," the Alliance wrote, noting that this in turn would have "a dramatic impact on minority and underserved communities, which disproportionally suffer from skin ulcers and other skin-related complications that require skin substitute products. Without this change, it is likely that these populations will see access to early treatment dwindle, leading to more amputations, more hospitalizations and poorer health outcomes."

See Alliance letter
Follow us on: